Literature DB >> 16546672

Brain kinetics of the new selective serotonin transporter tracer [(123)I]ADAM in healthy young adults.

Jan Booij1, Maartje M L de Win.   

Abstract

UNLABELLED: Recently, the tracer (123)I-2-([2-({dimethylamino}methyl)phenyl]thio)-5-iodophenylamine ([(123)I]ADAM) has been developed for selective imaging of serotonin transporters (SERTs) with single photon emission computed tomography (SPECT). The purpose of this study was to develop an [(123)I]ADAM SPECT protocol for clinical studies in young adults.
METHODS: We examined the time course of [(123)I]ADAM binding to central SERTs in eight healthy young volunteers up to 6 h postinjection.
RESULTS: We found that the time of peak-specific [(123)I]ADAM binding was highly variable among subjects, but specific binding in the SERT-rich (hypo)thalamus peaked within 5 h postinjection in all subjects. Moreover, in this brain area, binding ratios of specific to nonspecific binding did not significantly change between 3 and 6 h postinjection, and peaked 5 h postinjection.
CONCLUSIONS: Five hours postinjection may be optimal for single-scan [(123)I]ADAM SPECT studies in humans, but more work is needed to assess the accuracy of the 5-h tissue ratio as a measure of SERT in the brain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546672     DOI: 10.1016/j.nucmedbio.2005.10.005

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  4 in total

1.  5-Chloro-2-(2'-((dimethylamino)methyl)-4'-iodophenylthio)benzenamine: a new serotonin transporter ligand.

Authors:  Shunichi Oya; Seok-Rye Choi; Mei-Ping Kung; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-02       Impact factor: 2.408

2.  Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls.

Authors:  Walter Koch; Marcus Unterrainer; Guoming Xiong; Peter Bartenstein; Markus Diemling; Andrea Varrone; John C Dickson; Livia Tossici-Bolt; Terez Sera; Susanne Asenbaum; Jan Booij; Ozlem L Kapucu; Andreas Kluge; Morten Ziebell; Jacques Darcourt; Flavio Nobili; Marco Pagani; Swen Hesse; Thierry Vander Borght; Koen Van Laere; Klaus Tatsch; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-08       Impact factor: 9.236

3.  The SPECT tracer [123I]ADAM binds selectively to serotonin transporters: a double-blind, placebo-controlled study in healthy young men.

Authors:  Elsmarieke van de Giessen; Jan Booij
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

4.  SERT-to-DAT ratios in early Parkinson's disease do not correlate with the development of dyskinesias.

Authors:  Sven R Suwijn; Henk W Berendse; Constant Vm Verschuur; Ania Winogrodzka; Rob Ma de Bie; Jan Booij
Journal:  EJNMMI Res       Date:  2013-06-05       Impact factor: 3.138

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.